January 07, 2026-- NeuraLight, the leader in developing precision biomarkers for neurology, today announced the completion of PALOMA, a pioneering study comparing eye-movement measures with standard ...

Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

Longtime Texas high school football coach Mike Robinson has died, DeSoto coach Claude Mathis confirmed to The Dallas Morning ...

PALOMA study is one of the largest longitudinal studies using eye-movement biomarkers in patients with Parkinson’s diseaseNEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--NeuraLight, the leader in ...

Tiziana Life Sciences (TLSA) announces the submission of its seventh annual Development Safety Update Report to the U.S. Food ...

Tiziana Life Sciences ( ($TLSA) ) just unveiled an update. On December 29, 2025, Tiziana Life Sciences reported that it has filed its seventh ...

Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec.

As of Friday, December 26, Alterity Therapeutics Limited’s ATHE share price has dipped by 6.30%, which has investors questioning if this is right time to buy.

Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, ...

FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to ...

Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi's tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to ...